Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19484272 | 1.00 | ACACB (0.40) | ACACBSCN10ALMNAL3MBTL1PDE2A | |
| SCHEMBL19479367 | 0.81 | HPGD (0.47) | ACACBLMNAL3MBTL1TRPV3 | |
| SCHEMBL19484455 | 0.81 | HPGD (0.47) | ACACBLMNAL3MBTL1TRPV3 | |
| SCHEMBL19484457 | 0.76 | KDM4E (0.42) | ACACBALDH1A1 | |
| SCHEMBL19480970 | 0.76 | ACACB (0.37) | ACACBL3MBTL1ALDH1A1 | |
| SCHEMBL19484456 | 0.76 | KDM4E (0.42) | ACACBALDH1A1 | |
| SCHEMBL19484458 | 0.76 | ACACB (0.37) | ACACBL3MBTL1ALDH1A1 | |
| SCHEMBL19480711 | 0.73 | SIGMAR1 (0.35) | ACACBLMNATRPV3 | |
| SCHEMBL19480704 | 0.73 | SIGMAR1 (0.35) | ACACBLMNATRPV3 | |
| SCHEMBL7600033 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787432-B2 | N-[(pyridyloxy)propanyl]benzamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-09-29 | — | — | US | disclosed |
| EP-3442958-B1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2020-05-06 | — | — | EP | disclosed |
| US-20190112291-A1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| WO-2017178340-A1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787432-B2 | N-[(pyridyloxy)propanyl]benzamides | HCRTR1, HCRTR2, CNR1 | ACACB 2623/4885SCN10A 686/4885LMNA 1670/4885 |
| US-20190112291-A1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | HCRTR1, HCRTR2, CNR1 | ACACB 2929/4885SCN10A 615/4885LMNA 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.